- Home
- SEMR vs NVCR Comparison
SEMR vs NVCR Comparison
Compare SEMR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEMR | NVCR |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SEMR | NVCR |
|---|---|---|
| Price | $11.93 | $14.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $13.80 | ★ $28.42 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 02-25-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $428,627,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $20.35 | $9.75 |
| Revenue Next Year | $14.87 | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.87 | 11.17 |
| 52 Week Low | $6.56 | $10.70 |
| 52 Week High | $18.74 | $30.78 |
Technical Indicators
Market Signals| Indicator | SEMR | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 80.51 | 65.38 |
| Support Level | $11.87 | $12.88 |
| Resistance Level | $11.90 | $13.64 |
| Average True Range (ATR) | 0.03 | 0.50 |
| MACD | -0.13 | 0.08 |
| Stochastic Oscillator | 81.25 | 95.83 |
Price Performance
Historical ComparisonAbout SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.